1. Hirota S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580 (1998).
2. Miettinen M., Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol. J. Pathol. 2003. № 54. Р. 3-24.
3. Архири П.П., Цымжитова Н.Ц., Стилиди И.С. и др. Клиническое и прогностическое значение мутационного статуса у больных гастроинтестинальными стромальными опухолями // Саркомы костей, мягких тканей и опухоли кожи. 2013. № 1. С. 42-46.
4. Arhiri P., Stilidi I.S., Poddubnaya I., Nikulin M.P., Tsymzhitova N., Mazurenko N.N. Clinical significance of mutational status in gastrointestinal stromal tumors (GIST). J. Clin. Oncol. 30, 2012 (suppl; abstr 20501).
5. Corless C.L., Barnett C.M., Heinrich M.C. (2011). Gastrointestinal stromal tumours: Origin and molecular oncology. Nature Reviews Cancer. 11(12), 865-878.
6. Corless C.L. Biology of gastrointestinal stromal tumors / Fletcher J.A., Heinrich MC. J. Clin. Oncol. 2004. Vol. 22. P. 3813-3825.
7. Corless C.L., Barnett C.M., Heinrich M.C. Gastrointestinal stromal tumours: origin and molecular oncology. Nature Reviews Cancer, 2011; doi: 10. 1038/nrc3143.
8. Lasota J. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs) / Miettinen M. // Semin. Diagn. Pathol. 2006. Vol. 23. P. 91-1.
9. Никулин М.П., Стилиди И.С. Гастроинтестинальные стромальные опухоли (ГИСО). Эпидемиология, диагностика, современные подходы к лечению // Современная онкология. Экстра-выпуск. 2007. С. 3-50.
10. Heikki J. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human pathology (2008) 39, 1411-1419.
11. Agaimy A. Minute, Wunsch P.H., Hofstaedter F. Gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am. J. Surg. Pathol. 2007. Vol. 31. P. 113-120.
12. Miettinen M., Lasota J. Gastrointestinal Stromal Tumors. Review on Morphology, Molecular Pathology, Prognosis, and Differential Diagnosis. Arch. Pathol. Lab. Med. 2006. № 130. Р. 1466-1476.
13. Стилиди И.С., Архири П.П., Никулин М.П. Хирургическое лечение больных с первичными локализованными и местнораспространенными гасроинтестинальными стромальными опухолями / Вестник РОНЦ им. Н.Н. Блохина РАМН. 2010. 21(1). С. 77-82.
14. Архири П.П., Стилиди И.С., Поддубная И.В. и др. Эффективность хирургического лечения больных с локализованными стромальными опухолями желудочно-кишечного тракта (ЖКТ) // Российский онкологический журнал. 2016. № 5. Т. 21. С. 233-237.
15. Eisenberg B.L. Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Ann. Surg. Oncol. 2004. № 11. Р. 465-475.
16. De Matteo R.P, Heinrich M.C, El-Rifai. W.M. Clinical management of gastro intestinal stromal tumors: before end after STI-571. Hum. Patho. J. 1999. № 30. Р. 1213-20.
17. De Matteo RP. Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000. Vol. 231. P. 51-8.
18. Demetri G., Benjamin R., Blanke C. et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) — update of the NCCN clinical practice guidelines....2007; 5 (Suppl 2): S1-S29.
19. Rutkowski P. Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience / Alessandro Gronchi, Peter Hohenberger, Sylvie Bonvalot, Patrick Schoffski, Sebastian Bauer, Elena Fumagalli, Pawel Nyckowski, Buu-Phuc Nguyen, Jan Martijn Kerst, Marco Fiore, Elzbieta Bylina, Mathias Hoiczyk, Annemieke Cats, Paolo G. Casali, Axel Le Cesne, Juorgen Treckmann, Eberhard Stoeckle, Johannes. H.W. de Wilt, Stefan Sleijfer, Ronald Tielen, Winette van der Graaf, Cornelis Verhoef, Frits van Coevorden // Ann. Surg. Oncol. (2013). 20: 2937-2943.
20. Corless C.L., Ballman K.V., Antonescu C. et al. Relation fo tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST). Results of the intergroup phase III trial ACOSOG Z9001 // J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2010. Vol. 28. № 15. Suppl. Abstract 10006.
21. Joensuu H., Eriksson M., Hatrmann J. et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J. Clin. Oncol. ASCO Annual Meeting Proceedings (PostMeeting Edition). 2011. Vol. 29. № 18. Suppl. Abstract LBA1.
22. Blay J.Y. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Cancer Treat. Rev. 2011. Vol. 37. № 5. P. 373-384.
23. Casali P.G., Jost L., Reichardt P., Schlemmer M., Blay J.Y. 2008. "ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment anf follow-up". Ann. Oncol., 19 Suppl.2. PP. 35-38.
24. Blanke C.D., Demetri G.D., von Mehren M. et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 2008; 26(4): 620-5.
25. Le Cesne A., Ray-Coquard I., Bui B.N. et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010. Vol. 11. № 10. P. 942-949.
26. Van Glabbeke M. Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analisys of 1,640 Patients. Journal of Clinical Oncology, Vol. 28, N7, March 1, 2010. P. 1247-1253.